tbuckley/cabot-search huggingface dataset:
SAT0193 Preliminary Results of Rally, A US Observational Study to Determine the Relative Safety Profile of Abatacept in Patients with Rheumatoid Arthritis: Table 1.
Authors: K. Michaud, R. Schumacher, F. Wolfe
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> As RCTs used for regulatory approval of RA treatments are not powered to provide serious adverse event rates, there is a need for large-scale observational safety studies. Because of strong channeling bias with new treatments, our study had matched controls to help better understand the long-term safety outcomes, as used in clinical practice, of abatacept (ABA), a selective T-cell co-stimulation modulator. We present preliminary results of our study describing baseline differences to help guide future analysis. <h3>Objectives</h3> We present preliminary results of our study describing baseline differences to help guide future analysis. <h3>Methods</h3> Patients with RA in the RAlly study were enrolled by their rheumatologist, and either started ABA or changed a DMARD or biologic disease modifiers (BDM) during 2009 through July 2014. Additional patients for both groups were added from the National Data Bank for Rheumatic Diseases (NDB). NDB controls were randomly matched by age, sex, and calendar date to NDB ABA patients in a 3:1 ratio. Control patients were separated into two groups allowing for possible overlap: DMARD (non-biologic) and BDM (biologic disease modifiers). <h3>Results</h3> We compared 1274 ABA patients (3830 pt-yrs) with 3656 controls (1346 DMARD, 3094 BDM). The baseline mean (SD) age was 62 (13) yrs, rheumatic disease comorbidity index was 2.1 (1.6), and 15% were male in the ABA group. Significant clinical differences between ABA vs. controls included HAQ 1.30 (0.7) vs. 1.15 (0.7), pain VAS 5.6 (2.7) vs. 4.7 (2.8), patient global 5.0 (2.5) vs. 4.3 (2.5), and prednisone use 47% vs. 38% (see Table). ABA was the first-ever biologic exposure for 16% (n=199), and was taken without concomitant DMARDs in 24% (306). The intravenous form of ABA was used by 91% (1156) and 13% (164) used the sub-cutaneous form available in 2012, with 4% (46) patients treated with both. <h3>Conclusions</h3> Preliminary results of our matched-controls safety study indicate that important differences remain in patients initiating ABA vs. other DMARDS and BDM in regular clinical practice. These differences, most notably prior medication exposure, prednisone use, comorbidities, and disease activity, should be accounted for when analyzing safety outcomes. <h3>Acknowledgements</h3> The RAlly study is funded by Bristol-Myers Squibb. <h3>Disclosure of Interest</h3> None declared
SP0101 Case 1 Presentation: What Symptoms do GPS See and what do they do?
Authors: S. Hider
Journal: Annals of the Rheumatic Diseases (2015)

This lecture will present several cases highlighting the frequency and range of musculoskeletal symptoms seen within primary care. The cases presented will also highlight issues regarding the role of primary care and use of investigations and referrals in the context of patients with arthralgia and suspected RA, prior to the discussion section which will elaborate on these issues in more detail. <h3>Disclosure of Interest</h3> None declared
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.
Authors: Annick Desjardins, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, Susan Boulton, Denise Lally-Goss, Frances McSherry, Eric S Lipp, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, Matthias Gromeier
Journal: Journal of Clinical Oncology (2015)

2068 Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. We report results of a dose finding study evaluating PVSRIPO delivered intratumorally by convection-enhanced delivery (CED). Methods: Eligible patients were adults with recurrent supratentorial GBM; solitary tumor 1-5cm in diameter; ≥ 4 weeks after chemotherapy, bevacizumab or study drug; adequate organ function; KPS > 70%; and positive anti-polio titer. The original two-step continual reassessment method dose escalation was amended to decrease to dose level -1 after observing prolonged steroid use in patients treated on higher dose levels. Results: Thus far, 20 patients have been treated (1 each at dose levels 1 and 3, 7 at level 2, 2 at level 4, 4 at level 5 and 5 at dose level -1). One dose-limiting toxicity was observed; a grade 4 intracranial hemorrhage at catheter removal (dose level 5). Adverse events possibly related to study include: pyramidal tract syndrome (grade 3, n = 5; grade 2, n = 1; grade 1, n = 1), seizure (grade 3, n = 1; grade 2, n = 1; grade 1, n = 8), lymphopenia (grade 3, n = 1), headache (grade 2, n = 4; grade 1, n = 4), dysphasia (grade 2, n = 3; grade 1, n = 6), paresthesia (grade 2, n = 3; grade 1, n = 5), concentration impairment (grade 2, n = 1; grade 1, n = 9), fatigue (grade 1, n = 7); one each of grade 2 diarrhea and hyperbilirubinemia; and one each of grade 1 fever, cough, nasal congestion, ataxia, eye pain, diplopia, homonymous hemianopia, thrombocytopenia, anemia, nausea and vomiting. Twelve patients remain alive, with pts #1 and #2 now more than 33 and 31 months post-PVSRIPO, respectively. Conclusions: Infusion of PVSRIPO via CED is safe thus far and encouraging efficacy results are observed. We are determining optimal phase II dosing. Clinical trial information: NCT01491893.
Correlates of stress reactivity in patients with bipolar disorder
Authors: J Swendsen, C Hammen, T Heller, M Gitlin
Journal: American Journal of Psychiatry (1995)

The authors examined individual differences in stress reactivity as well as whether features of the illness itself or psychological characteristics differentiate between patients with bipolar disorder who are highly stress reactive and those who are not.They assessed stressors and bipolar episodes in 58 patients with bipolar disorder followed for at least 1 year.Not only did stress level predict relapse, so did personality variables such as introversion and obsessionality and their interaction with stress. Number of previous episodes of bipolar illness, however, did not affect stress response.These results are not consistent with the view that episodes of bipolar disorder become increasingly independent of stressors after initial episodes. However, psychological traits may affect reactivity to stressors.
Particulate Matter Exposure and Cardiopulmonary Differences in the Multi-Ethnic Study of Atherosclerosis
Authors: Carrie P. Aaron, Yana Chervona, Steven M. Kawut, Ana V. Diez Roux, Mingwu Shen, David A. Bluemke, Victor C. Van Hee, Joel D. Kaufman, R. Graham Barr
Journal: Environmental Health Perspectives (2016)

Particulate matter (PM) exposure may directly affect the pulmonary vasculature. Although the pulmonary vasculature is not easily measurable, differential associations for right ventricular (RV) and left ventricular (LV) mass may provide an indirect assessment of pulmonary vascular damage.We tested whether long-term exposure to PM < 2.5 μm (PM2.5) is associated with greater RV mass and RV mass/end-diastolic volume ratio relative to the LV.The Multi-Ethnic Study of Atherosclerosis performed cardiac magnetic resonance (CMR) imaging among participants 45-84 years old without clinical cardiovascular disease in 2000-2002 in six U.S. cities. A fine-scale spatiotemporal model estimated ambient PM2.5 exposure in the year before CMR; individually weighted estimates accounted for indoor exposure to ambient PM2.5. Linear regression models were adjusted for demographics, anthropometrics, smoking status, cardiac risk factors, and LV parameters, with additional adjustment for city.The 4,041 included participants had a mean age of 61.5 years, and 47% were never smokers. The mean ambient PM2.5 was 16.4 μg/m3 and individually weighted PM2.5 was 11.0 μg/m3. PM2.5 exposure was associated with greater RV mass [ambient: 0.11 g per 5 μg/m3 (95% CI: -0.05, 0.27); individually weighted: 0.20 g per 5 μg/m3 (95% CI: 0.04, 0.36)] and a greater RV mass/end-diastolic volume ratio conditional on LV parameters. City-adjusted results for RV mass were of greater magnitude and were statistically significant for both measures of PM2.5, whereas those for RV mass/end-diastolic volume ratio were attenuated.Long-term PM2.5 exposures were associated with greater RV mass and RV mass/end-diastolic volume ratio conditional on the LV; however, additional adjustment for city attenuated the RV mass/end-diastolic volume findings. These findings suggest that PM2.5 exposure may be associated with subclinical cardiopulmonary differences in this general population sample.Aaron CP, Chervona Y, Kawut SM, Diez Roux AV, Shen M, Bluemke DA, Van Hee VC, Kaufman JD, Barr RG. 2016. Particulate matter exposure and cardiopulmonary differences in the Multi-Ethnic Study of Atherosclerosis. Environ Health Perspect 124:1166-1173; http://dx.doi.org/10.1289/ehp.1409451.
AB0813 Significantly Higher Local and Systemic Inflammation in RA Patients Compared with Polyarticular PSA Patients in Clinical Remission Under Anti-TNF Treatment
Authors: J. Ramírez García, J. Inciarte-Mundo, A. Cuervo, V. Ruiz-Esquide, M.V. Hernández, R. Sanmartí, J.D. Cañete
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To analyse clinical, serological and sonographic differences in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) on anti-TNF therapy. <h3>Methods</h3> Patients diagnosed with RA or PsA in clinical remission (DAS28-ESR&lt;2.6) on anti-TNF therapy were included. Angiogenic and proinflammatory cytokines were determined by Multiplex ELISA and compared with the same measurement in two control cohorts: active RA patients (DAS28&gt;3.2) and healthy people. Ultrasound scans of both hands were performed in all participants, with scoring of synovial hypertrophy (SH) (grades 0-3) and power Doppler (PD) signal (grades 0-3). <h3>Results</h3> 30 RA and 47 PsA patients in clinical remission, 22 clinically-active (DAS28-ESR&gt;3.2) RA patients and 20 healthy controls were included. RA patients in clinical remission had significantly higher disease activity (2.01 and 1.74, mean DAS28-ESR for RA and PsA, respectively, p=0.006) and higher levels of both proinflammatory (IL6, TNF, IL17F, IL23 and IL33) and angiogenic cytokines (Angiogenin, ANGPTL4, CXCL16, ENA78, PIGF and SDF1) compared with PsA patients in clinical remission. No differences were found in these mediators between PsA and healthy controls, whereas in RA patients in clinical remission these mediators were more similar to clinically active RA. Globally, 31 patients had a PD signal and 12 had SH≥2 plus PD, meeting the criteria of ultrasound-defined active synovitis (UdAS)]. Only 1 PsA patient met UdAS criteria compared with 11 RA patients in clinical remission (p=0.0001). Patients with UdAS had significantly higher levels of IL-6, IL-20, PIGF and SDF1. More PsA patients were receiving low doses of biologics (63.8%), and more frequently as monotherapy (72.3%) compared with RA patients in clinical remission (26.6% and 20%, respectively). <h3>Conclusions</h3> Clinical remission is qualitatively different in RA and PsA receiving TNF antagonist therapy. PsA patients had significantly-lower serum levels of angiogenic and proinflammatory cytokines and less ultrasound synovitis than RA patients. A significantly-higher percentage of PsA patients were receiving low doses of biologics, mainly with monotherapy compared with RA patients in remission. Patients with chronic inflammatory polyarthritis in clinical remission with UdAS had higher serum levels of angiogenic/proinflammatory biomarkers, supporting the idea that this reflects true active synovitis. <h3>Disclosure of Interest</h3> None declared
Graduate Medical Education
Authors: L D Fenninger, R H Tracy
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ductal Carcinoma In Situ Stage 0 Breast Cancer
Authors: Jan Vick Harris
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Cytokine priming of acute myeloid leukemia may produce a pulmonary syndrome when associated with a rapid increase in peripheral blood myeloblasts [letter]
Authors: JS Wiley, GP Jamieson, JS Cebon, RK Woodruff, JJ McKendrick, J Szer, J Gibson, WP Sheridan, JC Biggs, MC Rallings
Journal: Blood (1993)
Can cellular transplantation improve function in doxorubicin-induced heart failure?
Authors: M Scorsin, A Hagege, I Dolizy, F Marotte, N Mirochnik, H Copin, M Barnoux, Marc Le Bert, J Samuel, L Rappaport, P Menasché
Journal: Circulation (1998)

Transplantation of fetal cardiomyocytes has been shown to improve function of regionally infarcted myocardium, but its effects on global heart failure are still unknown.Heart failure was induced in female mice by intraperitoneal injection of doxorubicin (2 mg/kg twice per week over 2 cycles of 2 weeks separated by a 2-week drug-free period). One week after the end of treatment, left ventricular function was assessed by transthoracic echocardiography (baseline). Animals were then randomized into 3 groups: The treated group (n = 12) received an intramyocardial injection of fetal cardiomyocytes (1 x 10(6) in 10 microL) harvested from transgenic mice expressing the gene of beta-galactosidase, the control group (n = 15) received an equivalent volume of culture medium alone, and 10 sham mice had no surgery. Two weeks and 1 month after transplantation, function was again assessed echocardiographically. At baseline, fractional shortening was not significantly different between the 3 groups. It then significantly increased in cell-treated mice at 2 weeks and 1 month after transplantation (P < 0.002 and P < 0.03 versus baseline, respectively), whereas it did not change in untreated animals. Transplanted cells could not be identified by beta-galactosidase activity or presence of Y chromosome (with 1 exception).Cellular transplantation can improve function of globally failing hearts by a mechanism that might not necessarily involve the sustained presence of transplanted cells but rather the effects of cardioprotective factors released by them.
Improved Methods for the Purification of Tumor-Localizing Antibodies2
Authors: Eugene D. Day, Glover W. Barnes, Jakob A. Planinsek, David Pressman
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Improved Methods for the Purification of Tumor-Localizing Antibodies Get access Eugene D. Day, Eugene D. Day Search for other works by this author on: Oxford Academic PubMed Google Scholar Glover W. Barnes, Glover W. Barnes Search for other works by this author on: Oxford Academic PubMed Google Scholar Jakob A. Planinsek, Jakob A. Planinsek Search for other works by this author on: Oxford Academic PubMed Google Scholar David Pressman David Pressman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 6, June 1958, Pages 1123–1139, https://doi.org/10.1093/jnci/20.6.1123 Published: 01 June 1958 Article history Received: 02 December 1957 Published: 01 June 1958
Mistakes
Authors: Ruth Lesnewski
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Laboratory Procedures.
Authors: E M Watson
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hyaluronic Acid Modified Hollow Prussian Blue Nanoparticles Loading 10-hydroxycamptothecin for Targeting Thermochemotherapy of Cancer
Authors: Lijia Jing, shangmin shao, Yang Wang, Yongbo Yang, Xiuli Yue, Zhifei Dai
Journal: Theranostics (2015)

This paper reported the fabrication of a multifunctional nanoplatform by modifying hollow Prussian blue nanoparticles with hyaluronic acid grafting polyethylene glycol, followed by loading 10-hydroxycamptothecin for tumor-targeted thermochemotherapy.It was found that the surface modification of hollow Prussian blue nanoparticles with hyaluronic acid grafting polyethylene endowed a great colloidal stability, long blood circulation time and the capability for targeting Hela cells over-expressing the CD44 receptor.The obtained nanoagent exhibited efficient photothermal effect and a light triggered and stepwise release behavior of 10-hydroxycamptothecin due to the strong optical absorption in the near-infrared region.The investigations on the body weight change, histological injury and blood biochemical indexes showed that such nanoagent had excellent biocompatibility for medical application.Both in vitro and in vivo experiments proved that the combination of chemotherapy and photothermal therapy through the agent of hyaluronic acid modified Prussian blue nanoparticles loading 10-hydroxycamptothecin could significantly improve the therapeutic efficacy compared with either therapy alone because of a good synergetic effect.
Caput Medusae
Authors: S M Cohen
Journal: New England Journal of Medicine (1999)

Figure 1 A 43-year-old man known to have hepatitis C infection and a long history of alcohol abuse was admitted to the hospital with ascites and edema. For the previous year he had noticed painless enlarged veins on his abdomen. Examination revealed spider angiomas, palmar erythema, enlarged parotid glands, edema, hepatosplenomegaly, ascites, and an unusually large caput medusae. Auscultation over the caput medusae revealed a Cruveilhier–Baumgarten murmur. Paracentesis yielded fluid that appeared to be a transudate. Abdominal ultrasonography revealed cirrhosis, hepatosplenomegaly, ascites, a recanalized umbilical vein, and patent hepatic veins. An abdominal computed tomographic scan showed a 3-mm recanalized umbilical vein with collaterals extending to the abdominal wall. The ascites responded adequately to moderate doses of oral diuretics. No treatment was deemed necessary for the caput medusae. During three months of follow-up, the patient's edema and ascites have continued to respond to oral diuretic therapy. Figure 1 A 43-year-old man known to have hepatitis C infection and a long history of alcohol abuse was admitted to the hospital with ascites and edema. For the previous year he had noticed painless enlarged veins on his abdomen. Examination revealed spider angiomas, palmar erythema, enlarged parotid glands, edema, hepatosplenomegaly, ascites, and an unusually large caput medusae. Auscultation over the caput medusae revealed a Cruveilhier–Baumgarten murmur. Paracentesis yielded fluid that appeared to be a transudate. Abdominal ultrasonography revealed cirrhosis, hepatosplenomegaly, ascites, a recanalized umbilical vein, and patent hepatic veins. An abdominal computed tomographic scan showed a 3-mm recanalized umbilical vein with collaterals extending to the abdominal wall. The ascites responded adequately to moderate doses of oral diuretics. No treatment was deemed necessary for the caput medusae. During three months of follow-up, the patient's edema and ascites have continued to respond to oral diuretic therapy. Stanley M. Cohen, M.D.Digestive Care Associates, Peoria, IL 61603